Celadon proposes delisting, re-registration as private company
2nd Jul 2025 11:26
(Sharecast News) - Celadon Pharmaceuticals announced on Wednesday that it intends to delist its shares from AIM and re-register as a private limited company, subject to shareholder approval.
Read moreCeladon Pharmaceuticals still facing cash crisis
30th Apr 2025 14:32
(Sharecast News) - Celadon Pharmaceuticals reiterated on Wednesday that it has yet to receive funds under its secured credit facility, and was still facing significant funding uncertainty, raising the prospect of administration if additional financing is not secured promptly.
Read moreCeladon still seeking finance as it draws down most of facility
31st Jan 2025 12:14
(Sharecast News) - Celadon Pharmaceuticals reported on Friday that it has received £0.897m of a £1m drawdown request from its committed credit facility, with the remaining £0.1m now expected in February.
Read moreCeladon Pharmaceuticals finance chief to step down
30th Sep 2024 11:08
(Sharecast News) - Celadon Pharmaceuticals announced on Monday that Jonathan Turner, its chief financial officer, was stepping down.
Read moreCeladon inks partnership with Denmark's Valeos
11th Sep 2024 15:52
(Sharecast News) - Celadon Pharmaceuticals announced a strategic collaboration with Danish pharmaceutical company Valeos Pharma on Wednesday, to accelerate the production and supply of high-THC medical cannabis across Europe.
Read moreCeladon confident in seeing through funding challenges
23rd Aug 2024 11:58
(Sharecast News) - Cannabis-based medicines specialist Celadon Pharmaceuticals updated the market on its financial position on Friday, amid ongoing challenges related to delays in expected funding.
Read moreCeladon Pharmaceuticals raises £2.1m for working capital
10th May 2024 11:48
(Sharecast News) - Medical cannabis specialist Celadon Pharmaceuticals announced on Friday that it has raised £2.1m to provide it with additional working capital.
Read moreCeladon starts supplying cannabis for two contracts
14th Dec 2023 11:16
(Sharecast News) - Medical cannabis specialist Celadon Pharmaceuticals has started supplying its pharmaceutical-grade product to two commercial contracts, first announced on 24 May and 5 September, it said on Thursday.
Read moreCeladon's new finance chief to join later in January
13th Jan 2023 13:24
(Sharecast News) - Celadon Pharmaceuticals updated the market on the arrival of its new finance chief on Friday.
Read moreCeladon confident in approval for its cannabis medicine facility
22nd Dec 2022 14:50
(Sharecast News) - Cannabis-based medicine developer Celadon Pharmaceuticals updated the market on its application for registration of its West Midlands facility with the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the 'Good Manufacturing Practices' (GMP) approval of its cannabis active pharmaceutical ingredient (API).
Read moreSummerway to buy medicinal cannabis group Vertigrow
28th Oct 2021 10:10
(Sharecast News) - Summerway Capital has agreed to buy Vertigrow Technology, a medicinal cannabis producer, for £80m to take the business public and expand it.
Read moreCaparo Energy obtains first phase of financing
20th Jun 2011 15:01
Caparo Energy has today disclosed that it has obtained a first round of financing, for Rs 3,500m (US$78.5m), from the India Infrastructure Fund. The mezzanine debt takes the form of preference shares with a six year term. Of note, the company has highlighted the non-dilutive nature of these prefer
Read moreCaparo Energy finalises debt facility
30th Dec 2010 10:05
India-focused wind power generation investor Caparo Energy unveiled a $0.44m loss in its first set of interim results since listing on AIM in November. The company has yet to make its first set of investments but remains in discussion with Suzlon Energy regarding the roll out schedule or the first
Read moreCaparo raises £50.2m in AIM float
12th Oct 2010 17:52
India-focused wind power generation investor Caparo Energy has joined AIM today after a £50.2m fund raising. The net proceeds of the placing at 115p a share were £46.3m. The cash will be spent on purchasing existing projects from Suzlon Energy and to provide working capital. The acquisition of fur
Read moreCelsis gets 232.5p cash offer
3rd Aug 2009 09:02
Diagnostics group Celsis has agreed to a cash offer worth 232.5p per share or £54.5m in total from private equity group North Atlantic Value. Celsis directors have recommended the offer. 'We see this offer of 232.5p as an excellent opportunity for Celsis Shareholders to realise the value of their C
Read more